6589 Stock Overview Operates as a contract development and manufacturing company in Taiwan and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
EirGenix Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for EirGenix Historical stock prices Current Share Price NT$80.50 52 Week High NT$100.50 52 Week Low NT$66.90 Beta 0.65 1 Month Change 11.81% 3 Month Change -12.31% 1 Year Change -13.90% 3 Year Change -19.90% 5 Year Change 174.28% Change since IPO 78.93%
Recent News & Updates
New minor risk - Share price stability Jan 30
USFDA Issues Study May Proceed Letter to EirGenix for the Phase III Clinical Trial of Developmental Product Eg1206a (Pertuzumab Biosimilar) Jan 24
EirGenix, Inc. Officially Submits NDA for the Biosimilar Drug EIRGASUN of 420 Mg Lyophilized Powder for Intraous Administration to the TFDA Jan 06
EirGenix Inc. Officially Submits the Phase III Clinical Trial Application for the Developmental Product EG1206A (pertuzumab Biosimilar) in US FDA Dec 26
New minor risk - Share price stability Dec 17
Consensus revenue estimates fall by 16% Dec 12 See more updates
New minor risk - Share price stability Jan 30
USFDA Issues Study May Proceed Letter to EirGenix for the Phase III Clinical Trial of Developmental Product Eg1206a (Pertuzumab Biosimilar) Jan 24
EirGenix, Inc. Officially Submits NDA for the Biosimilar Drug EIRGASUN of 420 Mg Lyophilized Powder for Intraous Administration to the TFDA Jan 06
EirGenix Inc. Officially Submits the Phase III Clinical Trial Application for the Developmental Product EG1206A (pertuzumab Biosimilar) in US FDA Dec 26
New minor risk - Share price stability Dec 17
Consensus revenue estimates fall by 16% Dec 12
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 15
EirGenix Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 17
EirGenix Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Consensus revenue estimates fall by 28% May 30
No longer forecast to breakeven May 29
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 18
EirGenix Inc. to Report Q1, 2024 Results on May 09, 2024 May 02
EirGenix Inc. to Report Q1, 2024 Results on May 09, 2024 May 01
Forecast breakeven date pushed back to 2025 Apr 23
Full year 2023 earnings: EPS misses analyst expectations Mar 26
EirGenix Inc., Annual General Meeting, May 30, 2024 Mar 09
Consensus revenue estimates fall by 18% Feb 06
Price target decreased by 16% to NT$133 Feb 05
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC Nov 23
Third quarter 2023 earnings: EPS exceeds analyst expectations Nov 15 Nov 15
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System Sep 20
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 10
Price target decreased by 7.5% to NT$172 Jun 09
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 21
Price target decreased by 9.8% to NT$175 Mar 15
EirGenix Inc. Announces Executive Changes Jan 12
Forecast breakeven date pushed back to 2023 Dec 31
Eirgenix Inc. Announces Establishment of Corporate Governance Committee Dec 29
Price target increased to NT$169 Nov 29
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Less than half of directors are independent Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 13
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee Sep 10
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 16 EirGenix Inc. Announces Board Appointments
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 16
Price target decreased to NT$129 Apr 27
Less than half of directors are independent Apr 27
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 03
EirGenix Inc. Announces Replacement of Representative of Juristic Person as Director Mar 30
Price target decreased to NT$129 Mar 19
EirGenix Inc. Officially Submitts for Phase I Pkbiosimilarity Clinical Study of Developmental Product EG1206A (Proposed Pertuzumab Biosimilar) in Europe Feb 07
Third quarter 2021 earnings released: EPS NT$1.36 (vs NT$0.34 loss in 3Q 2020) Nov 15
EirGenix Inc. announced that it expects to receive TWD 2.51625 billion in funding from Foxconn Technology Co., Ltd. Sep 24
Second quarter 2021 earnings released: NT$0.65 loss per share (vs NT$1.74 loss in 2Q 2020) Aug 15
First quarter 2021 earnings released: NT$1.11 loss per share (vs NT$2.06 loss in 1Q 2020) May 18
Consensus EPS estimates fall to -NT$3.41 Apr 13
Market Sentiment Around Loss-Making EirGenix Inc. (GTSM:6589) Apr 08
Full year 2020 earnings released: NT$5.41 loss per share (vs NT$5.39 loss in FY 2019) Mar 27
Is EirGenix (GTSM:6589) Using Debt Sensibly? Mar 03
New 90-day high: NT$54.20 Feb 19
New 90-day low: NT$39.05 Jan 22
Should EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit? Jan 07
New 90-day low: NT$44.35 Jan 04
New 90-day low: NT$49.15 Dec 09
Revenue beats expectations, earnings disappoint Nov 14
Third quarter 2020 earnings released: NT$0.34 loss per share Nov 14
New 90-day low: NT$52.50 Nov 01
New 90-day high - NT$65.40 Aug 28
First half earnings released Aug 15 Shareholder Returns 6589 TW Life Sciences TW Market 7D 0% 0% 0% 1Y -13.9% -15.7% 28.6%
See full shareholder returns
Return vs Market: 6589 underperformed the TW Market which returned 28.6% over the past year.
Price Volatility Is 6589's price volatile compared to industry and market? 6589 volatility 6589 Average Weekly Movement 6.1% Life Sciences Industry Average Movement 6.0% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 6589's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6589's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
Show more EirGenix Inc. Fundamentals Summary How do EirGenix's earnings and revenue compare to its market cap? 6589 fundamental statistics Market cap NT$24.65b Earnings (TTM ) -NT$986.69m Revenue (TTM ) NT$1.17b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6589 income statement (TTM ) Revenue NT$1.17b Cost of Revenue NT$891.55m Gross Profit NT$279.34m Other Expenses NT$1.27b Earnings -NT$986.69m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.22 Gross Margin 23.86% Net Profit Margin -84.27% Debt/Equity Ratio 6.0%
How did 6589 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 12:13 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources EirGenix Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jianzheng Wu Capital Securities Corporation null null KGI Securities Co. Ltd. Hsuan Chen KGI Securities Co. Ltd.
Show 2 more analysts 
